Four scientist in a laboratory discussing the work

A new frontier
in drug formulation

The Dispersome® technology allows formulation of poorly soluble small molecule drugs into stable amorphous formulations with a high drug load.

Dispersome® - An enabling technology for low solubility drugs

DISPERSOME® PLATFORM

Our Dispersome® platform is based around a class of novel excipients to formulate poorly soluble small molecule drugs into stable amorphous formulations with a high drug load.

IMPROVING OUTCOMES

By increasing solubility and dissolution rate the Dispersome® platform aims at improving bioavailability, therapeutic outcomes and convenience for patients.

COMPATIBLE TECHNOLOGY

Dispersome® formulations are compatible with standard solid oral dosage form manufacturing processes and facilities.

Meet us at upcoming events

New updates in Drug Formulation & Bioavailability, Copenhagen

🗓
Sep 6
-
Sep 6
📍
Copenhagen
Read More

Formulation & Drug Delivery Congress, USA

🗓
Oct 11
-
Oct 12
📍
San Diego
Read More

CPhI worldwide, Frankfurt

🗓
Nov 1
-
Nov 3
📍
Frankfurt
Read More

About Zerion Pharma

Zerion is a pharmaceutical development company improving the formulation of poorly soluble drugs (oral solid dosage forms) that are currently not reaching their therapeutic potential. Through the use of our proprietary formulation platform, Dispersome®, we aim to develop new treatment options for patients across all therapeutic areas.

Learn more

Our technology

Up to 90 % of all new drug molecules are poorly soluble, which can be a problem as the drug must dissolve in order to be absorbed and reach its pharmacological target.

Learn more

Zerion Pharma News

Press Releases
|
February 23, 2022

Arla Foods Ingredients and Zerion Pharma complete long-term supply agreement for beta-lactoglobulin (Lacprodan® BLG-100)

February 23, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) announces today that it has executed a long-term agreement with Arla Foods Ingredients covering the supply of its Lacprodan® BLG-100 for use as

____________________
|
February 22, 2022

Zerion Pharma and Hovione form strategic partnership to market and commercialise the proprietary Dispersome® technology platform

February 22, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (ZERION), a Danish drug development company, is pleased to announce today to have entered into a strategic partnership with HOVIONE, a leading global specia

____________________
Press Releases
|
January 10, 2022

New study shows that the amount of active drug in cancer tablets may be reduced by 75% using the Dispersome® technology

January 10, 2022 (COPENHAGEN, Denmark). The Danish drug development company, Zerion Pharma A/S (ZERION) has completed a new animal study (in dogs) that clearly demonstrates the potential of its patented Dispersome®

____________________
More news

Zerion Pharma in Press